Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BPMC Stock Forecast 2026-2027
$129.46
Current Price
$8.37B
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BPMC Price Targets
+4.3%
To High Target of $135.00
-0.4%
To Median Target of $129.00
-0.4%
To Low Target of $129.00
BPMC Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+1.2%
1 Year Change
0.0%
Year-to-Date Change
-0.1%
From 52W High of $129.65
+77.2%
From 52W Low of $73.04
📊 TOP ANALYST CALLS
Did BPMC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Blueprint Medicines is one of their latest high-conviction picks.
Latest BPMC Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, BPMC has a neutral consensus with a median price target of $129.00 (ranging from $129.00 to $135.00). The overall analyst rating is Buy (6.0/10). Currently trading at $129.46, the median forecast implies a -0.4% downside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sudan Loganathan at Stephens & Co., projecting a 4.3% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 0.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BPMC Analyst Ratings
0
Buy
1
Hold
0
Sell
BPMC Price Target Range
Low
$129.00
Average
$129.00
High
$135.00
Current: $129.46
Latest BPMC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BPMC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 17, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $129.00 |
| Jun 5, 2025 | UBS | David Dai | Neutral | Maintains | $129.00 |
| Jun 5, 2025 | Morgan Stanley | Judah Frommer | Equal-Weight | Maintains | $129.00 |
| Jun 4, 2025 | Citigroup | David Lebowitz | Neutral | Upgrade | $129.00 |
| Jun 3, 2025 | JMP Securities | Reni Benjamin | Market Perform | Downgrade | $N/A |
| Jun 3, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $N/A |
| Jun 3, 2025 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Downgrade | $135.00 |
| Jun 2, 2025 | JP Morgan | Brian Cheng | Neutral | Downgrade | $129.00 |
| Jun 2, 2025 | Scotiabank | Louise Chen | Sector Perform | Downgrade | $135.00 |
| Jun 2, 2025 | Needham | Ami Fadia | Hold | Downgrade | $130.00 |
| Jun 2, 2025 | Wedbush | David Nierengarten | Neutral | Downgrade | $129.00 |
| May 2, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
| Apr 28, 2025 | Needham | Ami Fadia | Buy | Maintains | $130.00 |
| Apr 16, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $128.00 |
| Apr 8, 2025 | Needham | Ami Fadia | Buy | Reiterates | $133.00 |
| Mar 20, 2025 | Morgan Stanley | Judah Frommer | Equal-Weight | Assumes | $100.00 |
| Mar 17, 2025 | Jefferies | Michael Yee | Buy | Initiates | $135.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $150.00 |
| Mar 3, 2025 | Citizens Capital Markets | Reni Benjamin | Market Outperform | Reiterates | $125.00 |
| Feb 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $135.00 |
Blueprint Medicines Corp. (BPMC) Competitors
The following stocks are similar to Blueprint Medicines based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BPMC
Blueprint Medicines
mkt cap
8.37B
Blueprint Medicines Corp. (BPMC) Financial Data
Blueprint Medicines Corp. has a market capitalization of $8.37B with a P/E ratio of -121.0x. The company generates $562.12M in trailing twelve-month revenue with a -27.7% profit margin.
Revenue growth is +55.5% quarter-over-quarter, while maintaining an operating margin of -27.5% and return on equity of -47.7%.
Valuation Metrics
Market Cap
$8.37B
Enterprise Value
$8.42B
P/E Ratio
-121.0x
PEG Ratio
1.2x
Price/Sales
14.9x
Growth & Margins
Revenue Growth (YoY)
+55.5%
Gross Margin
+98.1%
Operating Margin
-27.5%
Net Margin
-27.7%
EPS Growth
-99.4%
Financial Health
Cash/Price Ratio
+6.9%
Current Ratio
2.8x
Debt/Equity
208.5x
ROE
-47.7%
ROA
-9.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Blueprint Medicines Corp. (BPMC) Business Model
About Blueprint Medicines Corp.
What They Do
Develops targeted therapies for cancers and rare diseases.
Business Model
The company generates revenue through the development and commercialization of targeted therapies that inhibit specific protein kinases responsible for disease progression. By focusing on genomically defined conditions, Blueprint Medicines aims to address significant unmet medical needs, particularly in oncology and hematology, which enhances its potential market reach and profitability.
Additional Information
Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines leverages its proprietary scientific platform and expertise in genomics and data science to deliver innovative treatments. The company is actively involved in addressing conditions such as systemic mastocytosis, gastrointestinal stromal tumors, and advanced thyroid cancers, making it a key player in precision medicine and attracting significant investor interest in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
682
CEO
Ms. Kathryn Haviland M.B.A.
Country
United States
IPO Year
2015
Website
www.blueprintmedicines.comBlueprint Medicines Corp. (BPMC) Latest News & Analysis
Latest News
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
8 months ago
Quick Summary
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) regarding its transaction with Sanofi, focusing on potential insider benefits and conflicts of interest.
Why It Matters
Concerns over insider benefits and potential conflicts in Blueprint's transaction with Sanofi may signal governance issues, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
9 months ago
Quick Summary
The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) regarding its transaction with Sanofi, focusing on potential insider benefits and conflicts of interest.
Why It Matters
Concerns over potential insider conflicts and benefits in Blueprint's transaction with Sanofi could impact stock performance and investor confidence, leading to scrutiny and volatility.
Source: Business Wire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
10 months ago
Quick Summary
Monteverde & Associates is investigating Blueprint Medicines' sale to Sanofi, which offers $129/share plus contingent value rights for future milestones.
Why It Matters
The investigation into Blueprint Medicines' sale to Sanofi raises concerns about the fairness of the deal, affecting shareholder confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of Blueprint Medicines Corporation to Sanofi, which offers shareholders $129.00 per share plus a contingent value right at closing.
Why It Matters
The investigation into Blueprint Medicines' sale to Sanofi may indicate potential issues with the deal, affecting share prices and investor confidence in both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Monteverde & Associates is investigating Blueprint Medicines' proposed sale to Sanofi for $129/share plus potential milestone payments via contingent value rights.
Why It Matters
Blueprint Medicines' sale to Sanofi at $129 per share plus potential CVR payments could affect stock valuation and investor sentiment, raising concerns over deal fairness and future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Blueprint Medicines (Nasdaq: BPMC) presented data highlighting over ten years of collaboration to advance treatments for systemic mastocytosis at a recent conference.
Why It Matters
Blueprint Medicines' presentations highlight advancements in systemic mastocytosis treatment, signaling strong expertise and potential growth, which may attract investor interest and impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BPMC Stock
What is Blueprint Medicines Corp.'s (BPMC) stock forecast for 2026?
Based on our analysis of 33 Wall Street analysts, Blueprint Medicines Corp. (BPMC) has a median price target of $129.00. The highest price target is $135.00 and the lowest is $129.00.
Is BPMC stock a good investment in 2026?
According to current analyst ratings, BPMC has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $129.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BPMC stock?
Wall Street analysts predict BPMC stock could reach $129.00 in the next 12 months. This represents a -0.4% decrease from the current price of $129.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Blueprint Medicines Corp.'s business model?
The company generates revenue through the development and commercialization of targeted therapies that inhibit specific protein kinases responsible for disease progression. By focusing on genomically defined conditions, Blueprint Medicines aims to address significant unmet medical needs, particularly in oncology and hematology, which enhances its potential market reach and profitability.
What is the highest forecasted price for BPMC Blueprint Medicines Corp.?
The highest price target for BPMC is $135.00 from Sudan Loganathan at Stephens & Co., which represents a 4.3% increase from the current price of $129.46.
What is the lowest forecasted price for BPMC Blueprint Medicines Corp.?
The lowest price target for BPMC is $129.00 from Derek Archila at Wells Fargo, which represents a -0.4% decrease from the current price of $129.46.
What is the overall BPMC consensus from analysts for Blueprint Medicines Corp.?
The overall analyst consensus for BPMC is neutral. Out of 33 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $129.00.
How accurate are BPMC stock price projections?
Stock price projections, including those for Blueprint Medicines Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 9:14 PM UTC